Delivering Evidence Based Care using artificial Intelligence to Patients with Diabetes and CardioVascular Comorbidities: The DECIDE-CV Innovation Project
Many people who have Type 2 Diabetes Mellitus (T2DM) are never diagnosed until the development of a major health problem develops. Among people with T2DM with cardiovascular risk factors, evidence-based therapies can prevent future cardiovascular diseases from occurring. Artificial intelligence (A.I) represents an opportunity to address these major public health issues. The “Delivering Evidence based Care using artificial Intelligence to Patients with Diabetes and CardioVascular comorbidities” (DECIDE-CV) Innovation Project is a collaboration between McGill University Health Centre (academia), HOP and Boehringer-Ingelheim (industries), The DECIDE-CV project will leverage A.I. and clinical trial expertise of the Quebec based HOP Tech by using their algorithms to screen electrocardiograms, neurophysiological signals, and biomarker labels to identify patients at risk of T2DM and integrate these algorithms into an electronic health care system. The DECIDE-CV project will be one of the first projects to develop a collaborative partnership to improve health of people with T2DM.